Alteogen to Attend Jefferies Conference for First Time, Seeks to Expand Hybrozyme

[Financial News] Alteogen will make its first appearance at a global healthcare investment event, seeking to expand the range of applications for its core technology, Hybrozyme, and forge global partnerships.
Alteogen said on the 13th that it will attend the 2026 Jefferies Global Healthcare Conference, which will be held in London, UK, from the 16th to the 19th.
Hosted by Jefferies, the event brings together global investment institutions and pharmaceutical and biotech companies to discuss investment and business collaboration opportunities. It is regarded as one of Europe's major healthcare investment events, and this is the first time Alteogen has attended after receiving an official invitation.
During the event, Alteogen plans to hold partnering meetings to expand the application areas and technological modalities of its Hybrozyme platform. It will explore ways to extend the technology, which has so far been used mainly for monoclonal antibody-based cancer drugs, to a range of therapeutic areas and drug types.
In particular, it plans to identify the potential development of subcutaneous (SC) formulations of antibody-drug conjugates (ADCs) as a key area for collaboration. After previously announcing the potential to develop subcutaneous formulations of ADCs using Hybrozyme at the 2026 European Society for Medical Oncology (ESMO) Congress, the company plans to continue concrete discussions on collaboration with relevant companies.
Alteogen will also broaden its engagement with global investment institutions. It plans to present the Hybrozyme platform's business performance and competitiveness and explain its mid- to long-term growth strategy, including securing follow-on pipelines and expanding its development, manufacturing and commercialization capabilities.
Alteogen CEO Jeon Tae-yeon said, "Through this event, we will directly introduce our platform's competitiveness and growth strategy to prospective partners and global investment institutions," adding, "We will identify collaboration opportunities to expand Hybrozyme's application areas and modalities and turn them into tangible business results."

[email protected] Jung Sang-hee Reporter